Jasper Therapeutics
JSPR
25 hedge funds and large institutions have $161M invested in Jasper Therapeutics in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
639% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $274K
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
150% more funds holding
Funds holding: 10 → 25 (+15)
57% more capital invested
Capital invested by funds: $102M → $161M (+$58.4M)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
5.72% more ownership
Funds ownership: 0% → 5.72% (+5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$5.05M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.52M |
| 3 |
GC
Grace Capital
Quincy,
Massachusetts
|
+$2.04M |
| 4 |
Morgan Stanley
New York
|
+$1.78M |
| 5 |
BlackRock
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.75M |
| 2 |
LPARFS
Leverage Partners Absolute Return Fund SPC
Cayman Islands Ky1-11111,
Cayman Islands
|
-$815K |
| 3 |
Jane Street
New York
|
-$267K |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$205K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$56.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Tudor Investment Corp
Stamford,
Connecticut
| – | -$205K | -2,000 | Closed |
|
|
LPARFS
27
Leverage Partners Absolute Return Fund SPC
Cayman Islands Ky1-11111,
Cayman Islands
| – | -$815K | -1,500 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -20 | Closed |
|
|
SIA
29
SkyView Investment Advisors
Shrewsbury,
New Jersey
| – | +$94 | +1 | New |
|
JSPR Hedge Fund Activity: Q4 2021 in Review
25 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2021, worth a combined $161M — up 57% from $102M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new JSPR positions and 4 closed out — a net gain of 15 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $5.05M. The largest seller was Federated Hermes, cutting an estimated $2.75M.
- 25 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2021, up from 10 in Q3 2021.
- Funds reported $161M of Jasper Therapeutics stock for Q4 2021, up 57% quarter-over-quarter.
- 19 funds opened new Jasper Therapeutics positions in Q4 2021 and 4 closed out, a net change of +15 holders.
- The largest Jasper Therapeutics buyer in Q4 2021 was Kingdon Capital Management, an estimated $5.05M added.
- The largest Jasper Therapeutics seller in Q4 2021 was Federated Hermes, an estimated $2.75M sold.
Based on aggregated 13F filings for Q4 2021.